论文部分内容阅读
目的:对孟鲁司特联合舒利迭治疗难治性支气管哮喘的临床效果展开分析。方法:选取2011年5月-2013年1月重庆市第十三人民医院收治的难治性支气管哮喘患者42例,分为治疗组和对照组,均为21例。治疗组采用孟鲁司特+舒利迭治疗,对照组采用舒利迭治疗,对两组患者临床治疗效果展开对比分析。结果:两组患者治疗后1s用力呼气容积(FEV1)、FEV1/用力肺活量(FVC)、咳嗽症状评分比较,差异有统计学意义(P<0.05);治疗组临床治疗总有效率高于对照组,组间比较差异有统计学意义(P<0.05)。结论:临床上采用孟鲁司特联合舒利迭治疗难治性支气管哮喘效果较为理想。
Objective: To analyze the clinical effect of Montelukast combined with seretide in the treatment of refractory bronchial asthma. Methods: Forty-two patients with refractory bronchial asthma were selected from the 13th People’s Hospital of Chongqing Municipality from May 2011 to January 2013, divided into treatment group and control group, all of which were 21 cases. The treatment group with montelukast + seretide treatment, the control group with seretide treatment, the clinical efficacy of the two groups were compared. Results: The forced expiratory volume (FEV1), FEV1 / FVC and cough symptom scores of the two groups after treatment were significantly different (P <0.05). The total effective rate of the treatment group was higher than that of the control group There were significant differences between groups (P <0.05). Conclusion: Montelukast combined with seretide in the treatment of refractory bronchial asthma is more ideal.